Evidence map›Paper›PMID 41867178›Full record

ArticlemedRxiv : the preprint server for health sciences2026

Early treatment outcome prediction in metastatic castration-resistant prostate cancer utilizing 3-month tumor growth rate (

Esther C Ugwueke, Mohamed Azzam, Mengxi Zhou, Benjamin A Teply, Raymond C Bergan, Shibiao Wan, Antonio Tito Fojo, Harshraj Leuva, Jieqiong Wang

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Esther C UgwuekeDepartment of Neurological Sciences, University of Nebraska Medical Center, Omaha, NE, USA.ORCID 0000-0002-5947-3422
Mohamed AzzamDepartment of Neurological Sciences, University of Nebraska Medical Center, Omaha, NE, USA.
Mengxi ZhouMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Benjamin A TeplyDepartment of Internal Medicine, Division of Medical Oncology/Hematology, University of Nebraska Medical Center, Omaha, NE, USA.
Raymond C BerganFred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA.
Shibiao WanDepartment of Genetics, Cell Biology and Anatomy, University of Nebraska Medical Center, Omaha, NE, USA.
Antonio Tito FojoDepartment of Medicine, Division of Hematology/Oncology, Columbia University Medical Center, New York, NY, USA.
Harshraj LeuvaDepartment of Internal Medicine, Division of Medical Oncology/Hematology, University of Nebraska Medical Center, Omaha, NE, USA.
Jieqiong WangDepartment of Neurological Sciences, University of Nebraska Medical Center, Omaha, NE, USA.

Funding

UNMC/EPPLEY CANCER CENTER SUPPORT GRANTP30CA036727 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI James Eudy · 1985 to 2026
$55.0M
Leveraging Heterogenous Common Fund Data Sets and Beyond for Identifying Lung Cancer SubtypesR03OD038391 · OD · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI WAN, SHIBIAO, WANG, JIEQIONG · 2024 to 2024
$307k
NCI NIH HHS P30 CA036727NIH HHS R03 OD038391
6 · The paper itself

Abstract

Background: Once the treatment starts, early prediction of treatment benefit and its correlation with overall survival (OS) remains challenging in metastatic castration-resistant prostate cancer (mCRPC). Existing prognostic models require long-term follow-up, limiting their ability to inform timely treatment decisions. To address this gap, we evaluated tumor growth rate ( Methods: We developed GxSurv, a Random Survival Forest (RSF)-based framework that incorporates baseline clinical variables and Findings: The study included 15912 treatment records from 11014 patients with mCPRC across four lines of therapy. We found that incorporation of Interpretation: Integrating Funding: U.S. National Science Foundation, National Institutes of Health, American Cancer Society.

Identifiers

PMID41867178
PMCPMC13004149

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.